Home » News » Conference Coverage » International Kidney Cancer Symposium » International Kidney Cancer Symposium (IKCS) 2015
International Kidney Cancer Symposium (IKCS) 2015
High-dose interleukin-2 (HD IL-2) continues to have a favorable safety profile compared with data in the original package insert.
Researchers are enrolling patients for part 2 of a phase 2 trial to compare dalantercept plus axitinib for treatment of renal cell carcinoma (RCC).
Final overall survival results of the RECORD-3 trial are consistent with results and support the standard sequence of sunitinib followed by everolimus.
Axitinib treatment may result in higher drug costs compared with everolimus.
A phase 2 trial is enrolling patients with renal cell carcinoma (mRCC) to compare the combination of axitinib plus TRC105 with axitinib alone.
Axitinib initiated at 5 mg twice daily resulted in toleration of higher daily doses with sustained efficacy in patients with metastatic renal cell carcinoma (mRCC).
Clinical outcomes with everolimus as a second targeted therapy were not significantly different in advanced renal cell carcinoma (aRCC).
A large percentage of real-world patients with metastatic renal cell carcinoma (mRCC) initially deferred systemic therapy.
Side effects with immunotherapy are different from, and in most cases of PD-1 inhibition, better than chemotherapy.
In a population-based setting, sunitinib and pazopanib have similar efficacy in first-line treatment of metastatic renal cell carcinoma (mRCC).
Open
Next post in International Kidney Cancer Symposium (IKCS) 2015
Close
Close more info about High-dose Interleukin-2 Continues To Be Safe, Effective First-Line mRCC Treatment
Loading...
Close more info about High-dose Interleukin-2 Continues To Be Safe, Effective First-Line mRCC Treatment
Loading...